Entereg development stopped for opioid bowel dysfunction
This article was originally published in Scrip
Executive Summary
Adolorwill not pursue further development of Entereg (alvimopan) to treat chronic opioid bowel dysfunction (OBD), the company said, causing its share price to slide by 33% on Nasdaq on December 18th.